Trial Information - Phase II

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy

Disease Specifics: (NSCLC)

Protocol ID: eFT508-0011

Sponsor: eFFECTOR Therapeutics

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724